Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 31 08 2020
revised: 16 09 2020
accepted: 17 09 2020
pubmed: 13 10 2020
medline: 21 4 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

An interesting enzyme of the endocannabinoid system is monoacylglycerol lipase (MAGL). This enzyme, which metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG), has attracted great interest due to its involvement in several physiological and pathological processes, such as cancer progression. Experimental evidences highlighted some drawbacks associated with the use of irreversible MAGL inhibitors in vivo, therefore the research field concerning reversible inhibitors is rapidly growing. In the present manuscript, the class of benzoylpiperidine-based MAGL inhibitors was further expanded and optimized. Enzymatic assays identified some compounds in the low nanomolar range and steered molecular dynamics simulations predicted the dissociation itinerary of one of the best compounds from the enzyme, confirming the observed structure-activity relationship. Biological evaluation, including assays in intact U937 cells and competitive activity-based protein profiling experiments in mouse brain membranes, confirmed the selectivity of the selected compounds for MAGL versus other components of the endocannabinoid system. An antiproliferative ability in a panel of cancer cell lines highlighted their potential as potential anticancer agents. Future studies on the potential use of these compounds in the clinical setting are also supported by the inhibition of cell growth observed both in cancer organoids derived from high grade serous ovarian cancer patients and in pancreatic ductal adenocarcinoma primary cells, which showed genetic and histological features very similar to the primary tumors.

Identifiants

pubmed: 33045662
pii: S0223-5234(20)30829-1
doi: 10.1016/j.ejmech.2020.112857
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Enzyme Inhibitors 0
Piperidines 0
Monoacylglycerol Lipases EC 3.1.1.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112857

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Carlotta Granchi (C)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Giulia Bononi (G)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Rebecca Ferrisi (R)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Eleonora Gori (E)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Giulia Mantini (G)

Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, DeBoelelaan 1117, 1081HV, Amsterdam, the Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per La Scienza, Via Giovannini 13, 56017, San Giuliano Terme, Pisa, Italy.

Sandra Glasmacher (S)

Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, CH-3012, Bern, Switzerland.

Giulio Poli (G)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Stefano Palazzolo (S)

Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy.

Isabella Caligiuri (I)

Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy.

Flavio Rizzolio (F)

Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy; Department of Molecular Sciences and Nanosystems, Ca' Foscari University, 30123, Venezia, Italy.

Vincenzo Canzonieri (V)

Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy; Department of Medical, Surgical and Health Sciences, Università Degli Studi di Trieste, Strada di Fiume 447, Trieste, Italy.

Tiziana Perin (T)

Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy.

Jürg Gertsch (J)

Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, CH-3012, Bern, Switzerland.

Andrea Sodi (A)

Department of Neurosciences, Psychology, Drug Research and Child Health Eye Clinic, University of Florence, AOU Careggi, 50139, Florence, Italy.

Elisa Giovannetti (E)

Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, DeBoelelaan 1117, 1081HV, Amsterdam, the Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per La Scienza, Via Giovannini 13, 56017, San Giuliano Terme, Pisa, Italy.

Marco Macchia (M)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Filippo Minutolo (F)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Tiziano Tuccinardi (T)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy. Electronic address: tiziano.tuccinardi@unipi.it.

Andrea Chicca (A)

Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, CH-3012, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH